Shire To Market Orphan Drug Following Jerini Acquisition

Not wanting to be left behind in the current spate of biotech acquisitions, UK based Shire has struck a deal to acquire German firm Jerini for EUR349mn (US$548mn). In what Jerini describes as a strategic partnership, the UK firm will pay EUR6.25 (US$9.81) per share - 73% more than Jerini's closing price on July 2

To read the full article, please choose one of the following options: